New drugs, new thinking for prostate cancer

Share this article:

Optimal treatment of older patients with recurrent prostate cancer now involves more of a decision process than in the past, say the authors of a review article in the journal Drugs & Aging (2012;29[11]:871-883).

Prostate cancer, the most common cancer in men, is most often diagnosed after age 65 years. Several new drugs have been approved for the treatment of this disease, but the unique characteristics of the elderly population must be considered when choosing a therapy, contend Elizabeth R. Kessler, MD, an oncology fellow at the University of Colorado Cancer Center (CU Cancer Center) in Aurora, Colorado, and CU Cancer Center colleague Thomas W. Flaig, MD. For example, new targeted therapies such as abiraterone and enzalutamide are able to selectively destroy cancer cells while sparing healthy tissue, yielding fewer side effects and resulting in greater tolerability by elderly patients.

Improved androgen blockade has increased overall survival in men with metastatic prostate cancer. However, clinicians should be aware that this therapy carries many of the same adverse effects as previous agents. Similarly, newer approaches with immunotherapy, radiopharmaceuticals, or second-generation androgen receptor blockers introduce a different adverse-effect profile for older patients.

“As data mature, these [agents] too may improve survival for patients with metastatic disease,” noted the researchers. “Throughout all stages of disease, one must keep in mind the unique needs of an older patient population.”

Share this article:
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters


What is this?

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Web Exclusives

Support team aids decision-making by caregivers of terminal cancer patients

Researchers devised an intervention that quickly integrates a cancer support team to guide caregivers and their patients through difficult end-of-life treatment and decisions.

Protein inhibition opens door for pancreatic cancer treatment

The protein galectin-1 has been identified as a possible therapeutic target for pancreatic cancer; new research has demonstrated that inhibiting this protein in mice with pancreatic cancer increased survival by 20%.

Noninvasive advanced image analysis may improve care for lung cancer patients

Lung cancer patients could receive more precise treatment, and their progress could be better tracked by using a new high-tech method of non-invasive medical imaging analysis, according to a new study.